Special Drug Use-Results Survey of Lipitor Tablets (ALWAYS)

Astellas

Status: Completed

Conditions: Hypercholesterolemia

Treatments: Drug: atrovastatin

Study type: Observational

Funder types: Industry

Identifiers

NCT01446679

LIP003

Details and patient eligibility

About

This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.

Full description

To confirm the low-density lipoprotein cholesterol (LDL-C)-lowering effect of 24 weeks of treatment with Lipitor®(Generic Name : atorvastatin calcium) Tablets and determine the rate of achievement of the category-specific target LDL-C level in patients with hypercholesterolemia; and to confirm the usefulness (efficacy and safety) of atorvastatin in patients who have not responded sufficiently to other statin therapies

Enrollment: 24,050 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients with hypercholesterolemia who have not achieved the category-specific target lipid level

Trial design

24,050 participants in 1 patient group

atrovastatin group

Description:

Who receive atrovastatin

Treatment:

Drug: atrovastatin